HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Effects of a new platelet-activating factor antagonist, UR-12670, on several endotoxic shock markers in rats.

Abstract
UR-12670 is a novel and potent PAF antagonist, eg., it displaces [3H]WEB-2086 from PAF receptors in rabbit platelet membranes (Ki = 0.6 nM) and inhibits PAF-induced increase in vascular permeability in rat trachea (100%), thymus (44%), seminal vesicles (100%) and stomach (54%) at a dose of 0.01 mg/kg i.v. Since PAF is thought to be an important mediator in endotoxic shock, the effect of pretreatment with UR-12670 on changes in vascular permeability, disseminated intravascular coagulation (DIC) and plasma biochemical parameters were determined in a rat model of acute endotoxemia. UR-12670 and the reference PAF antagonist, lexipafant (10 mg/kg i.v.), strongly inhibited lipopolysaccharide (LPS, 25 mg/kg i.v.)-induced plasma leakage in the trachea (49 and 100%, respectively) and seminal vesicles (81 and 100%), as assessed by the Evans blue extravasation method. Only lexipafant inhibited the increase in vascular permeability in the thymus (36%). Neither PAF antagonist was effective in the stomach. Both UR-12670 and lexipafant at 10 mg/kg i.v. attenuated the LPS-induced variation of some DIC markers, such as activated partial thromboplastin time increase (56 and 58%, respectively) and the fibrinogen concentration decrease (53 and 31%), whereas the increase in prothrombin time was not affected. Increased plasma acid phosphatase (ACP, a lysosomal activation marker) and lactate dehydrogenase (LDH, a tissue damage marker) activity elicited by LPS was attenuated by pretreatment with 10 mg/kg i.v. of either UR-12670 or lexipafant (ACP: 55 and 48%; LDH: 50 and 33%). LPS-induced hyperglycemia (46 and 37%) and hyperlactacidemia (100% both) were also inhibited. UR-12670 protected against several shock symptoms, confirming the role of PAF in the pathogenesis of rodent endotoxemia.
AuthorsD Balsa, M Merlos, M Giral, R Ferrando, J Garcia-Rafanell, J Forn
JournalDrugs under experimental and clinical research (Drugs Exp Clin Res) Vol. 23 Issue 5-6 Pg. 191-9 ( 1997) ISSN: 0378-6501 [Print] Switzerland
PMID9515229 (Publication Type: Journal Article)
Chemical References
  • Blood Glucose
  • Imidazoles
  • Lipopolysaccharides
  • Platelet Activating Factor
  • Platelet Aggregation Inhibitors
  • Pyridines
  • UR 12670
  • Lactic Acid
  • Evans Blue
  • L-Lactate Dehydrogenase
  • Acid Phosphatase
Topics
  • Acid Phosphatase (blood)
  • Animals
  • Blood Glucose (metabolism)
  • Capillary Permeability (drug effects)
  • Evans Blue
  • Extravasation of Diagnostic and Therapeutic Materials
  • Imidazoles (pharmacology)
  • L-Lactate Dehydrogenase (blood)
  • Lactic Acid (blood)
  • Lipopolysaccharides (pharmacology)
  • Male
  • Partial Thromboplastin Time
  • Platelet Activating Factor (antagonists & inhibitors)
  • Platelet Aggregation Inhibitors (pharmacology)
  • Prothrombin Time
  • Pyridines (pharmacology)
  • Rats
  • Rats, Sprague-Dawley
  • Shock, Septic (blood, drug therapy, physiopathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: